Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jclinane.2024.111411 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid Sterilization of Clinical Apheresis Blood Products using Ultra-High Dose Rate Radiation.
bioRxiv
December 2024
Stanford Blood Center, Stanford Health Care, Stanford, California, USA.
Background And Objectives: Apheresis platelets products and plasma are essential for medical interventions, but both still have inherent risks associated with contamination and viral transmission. Platelet products are vulnerable to bacterial contamination due to storage conditions, while plasma requires extensive screening to minimize virus transmission risks. Here we investigate rapid irradiation to sterilizing doses for bacteria and viruses as an innovative pathogen reduction technology.
View Article and Find Full Text PDFEvaluation of the efficacy of convalescent plasma in moderate to severe COVID-19 during 2020-2021: a retrospective observational study.
Monaldi Arch Chest Dis
December 2024
Lab Operations and Microbiology, Agilus Diagnostics, Fortis Hospital, Noida, Uttar Pradesh.
Convalescent plasma therapy (CPT) is one of the treatment modalities used for COVID-19. Initial smaller studies showed the usefulness of CPT in COVID-19, but larger studies showed that it is not effective. This is a retrospective observational study conducted between 1st June 2020 and 31st July 2021 at a tertiary hospital in Noida, India.
View Article and Find Full Text PDFCurrent perspectives on vaccines and therapeutics for Lassa Fever.
Virol J
December 2024
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.
View Article and Find Full Text PDFUse of convalescent plasma in COVID-19 treatment: is clinical severity more important than the intervention?
Einstein (Sao Paulo)
December 2024
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Objective: This study compared the outcomes of two cohorts of patients with coronavirus disease 2019 (COVID-19) who received COVID-19 convalescent plasma transfusions between 2020 and 2021.
Methods: This retrospective study was conducted at a tertiary hospital in São Paulo, Brazil. We included a retrospective cohort of patients who received convalescent compassionate plasma, and another group of patients from a previous clinical study.
The Safety Profile of COVID-19 Convalescent Plasma.
Curr Top Microbiol Immunol
December 2024
Department of Health and Kinesiology, University of Illinois Urbana-Champaign, Urbana, IL, USA.
Despite concerns about potential side effects, based both on historical experience with plasma products and more recent concerns about contemporary use of plasma, COVID-19 convalescent plasma has been shown to be a very safe product. Research early in the COVID-19 pandemic documented-among the very large population of convalescent plasma recipients in the US Convalescent Plasma Study component of the FDA-authorized Expanded Access Program-that the overall risk profile was no different than that seen for fresh frozen plasma, a product used routinely in medical practice. The safety of CCP was further demonstrated using real-world evidence, pragmatic trials, and formal randomized trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!